Format

Send to

Choose Destination
Surg Oncol. 2018 Mar;27(1):100-105. doi: 10.1016/j.suronc.2017.12.005. Epub 2018 Jan 31.

Application of the 8th edition of the AJCC yTNM staging system shows improved prognostication in a single center cohort of esophageal carcinomas.

Author information

1
Department of Visceral Surgery and Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland.
2
Department of Visceral Surgery and Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland; Institute of Pathology, Department of Clinical Pathology, University of Bern, Switzerland.
3
Institute of Pathology, Department of Clinical Pathology, University of Bern, Switzerland.
4
Institute of Pathology, Department of Clinical Pathology, University of Bern, Switzerland. Electronic address: rupert.langer@pathology.unibe.ch.

Abstract

BACKGROUND:

The 8th edition of the AJCC TNM staging system presents for the first time a specific classification for esophageal carcinomas treated with neoadjuvant therapy (yTNM8). In this single center study, we applied the novel staging system in a "real life" case series and compared the prognostic value of yTNM8 with the preceding 7th edition (TNM7).

METHODS:

Out of 272 consecutive esophageal carcinomas that were treated during a 15-year period in one surgical center, all 198 cases that had undergone neoadjuvant therapy were reviewed and classified according to TNM7 and yTNM8.

RESULTS:

50 ypT0 cases that had no specific staging in TNM7 were included into stages I (ypT0N0M0; n = 42), IIIA (ypT0N1M0; n = 6), IVA (ypT0N3M0; n = 1) and IVB (ypT0N0M1; n = 1) in yTNM8. Both systems showed significant prognostic impact (p < 0.0001 each). yTNM8 was superior regarding prognostication with lower values for goodness-of-fit criteria (Akaike Information Criterion 1589.331 vs 1593.239; and Schwarz Bayesian Criterion 1605.487 vs.1619.088). However, in TNM7, stage IIB tumors had better prognosis than stage IIA tumors, and likewise, stage IIIA tumors better compared to stage II in yTNM8.

CONCLUSIONS:

yTNM8 allows accurate staging of esophageal carcinomas treated by neoadjuvant therapy, with slightly improved prognostication compared to TNM7. Additional data acquisition will be necessary for further improvement of staging for esophageal carcinomas after neoadjuvant treatment.

KEYWORDS:

Esophageal carcinoma; Neoadjuvant therapy; Staging; TNM

PMID:
29549896
DOI:
10.1016/j.suronc.2017.12.005
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center